The function of human epidermal growth factor receptor-3 and its role in tumors (Review)
- Authors:
- Qin Li
- Zhenyan Yuan
- Bangwei Cao
-
Affiliations: Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, P.R. China - Published online on: September 30, 2013 https://doi.org/10.3892/or.2013.2754
- Pages: 2563-2570
This article is mentioned in:
Abstract
 |
 |
|
Olayioye MA, Neve RM, Lane HA and Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19:3159–3167. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell. 103:211–225. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Marmor MD, Skaria KB and Yarden Y: Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys. 58:903–913. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Shepard HM, Brdlik CM and Schreiber H: Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest. 118:3574–3581. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Kraus MH, Issing W, Miki T, Popescu NC and Aaronson SA: Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA. 86:9193–9197. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Plowman GD, Whitney GS, Neubauer MG, et al: Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc Natl Acad Sci USA. 87:4905–4909. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Ullrich A, Coussens L, Hayflick JS, et al: Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 309:418–425. 1984. View Article : Google Scholar : PubMed/NCBI | |
|
Coussens L, Yang-Feng TL, Liao YC, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 230:1132–1139. 1985. View Article : Google Scholar : PubMed/NCBI | |
|
Cho HS and Leahy DJ: Structure of the extracellular region of HER3 reveals an interdomain tether. Science. 297:1330–1333. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Chen WS, Lazar CS, Lund KA, et al: Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation. Cell. 59:33–43. 1989. View Article : Google Scholar | |
|
Yoo J, Wang X, Rishi A, et al: Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin. Br J Cancer. 82:683–690. 2000.PubMed/NCBI | |
|
Jura N, Shan Y, Cao X, Shaw DE and Kuriyan J: Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci USA. 106:21608–21613. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Red Brewer M, Choi SH, Alvarado D, et al: The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell. 34:641–651. 2009.PubMed/NCBI | |
|
Jones RB, Gordus A, Krall JA and MacBeath G: A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature. 439:168–174. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sierke SL, Cheng K, Kim HH and Koland JG: Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem J. 322:757–763. 1997.PubMed/NCBI | |
|
Prigent SA and Gullick WJ: Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J. 13:2831–2841. 1994. | |
|
Citri A, Skaria KB and Yarden Y: The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res. 284:54–65. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Manning G, Whyte DB, Martinez R, Hunter T and Sudarsanam S: The protein kinase complement of the human genome. Science. 298:1912–1934. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Kornev AP and Taylor SS: Pseudokinases: functional insights gleaned from structure. Structure. 17:5–7. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Shi F, Telesco SE, Liu Y, Radhakrishnan R and Lemmon MA: ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA. 107:7692–7697. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Dawson JP, Berger MB, Lin CC, Schlessinger J, Lemmon MA and Ferguson KM: Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol. 25:7734–7742. 2005. View Article : Google Scholar | |
|
Carrasco-García E, Saceda M, Grasso S, et al: Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. Exp Cell Res. 317:1476–1489. 2011.PubMed/NCBI | |
|
Baselga J and Swain SM: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 9:463–475. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Opresko L, Shankaran H, Chrisler WB, Wiley HS and Resat H: HER/ErbB receptor interactions and signaling patterns in human mammary epithelial cells. BMC Cell Biol. 10:782009. View Article : Google Scholar : PubMed/NCBI | |
|
Lee D, Yu M, Lee E, et al: Tumor-specific apoptosis caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal epithelium. J Clin Invest. 119:2702–2713. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Vivanco I and Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Miller TW, Pérez-Torres M, Narasanna A, et al: Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res. 69:4192–4201. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lowenstein EJ, Daly RJ, Batzer AG, et al: The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell. 70:431–442. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Batzer AG, Rotin D, Ureña JM, Skolnik EY and Schlessinger J: Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol. 14:5192–5201. 1994.PubMed/NCBI | |
|
Hallberg B, Rayter SI and Downward J: Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation. J Biol Chem. 269:3913–3916. 1994.PubMed/NCBI | |
|
Liebmann C: Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity. Cell Signal. 13:777–785. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Pearson G, Robinson F, Beers Gibson T, et al: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 22:153–183. 2001.PubMed/NCBI | |
|
Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F and Mok T: Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. Lung Cancer. 72:3–8. 2011. View Article : Google Scholar | |
|
Tejani MA, Cohen RB and Mehra R: The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. Biologics. 4:173–185. 2010.PubMed/NCBI | |
|
Lièvre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 26:374–379. 2008. | |
|
Pirker R, Pereira JR, Szczesna A, et al: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 373:1525–1531. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar | |
|
Ji XD, Li G, Feng YX, et al: EphB3 is overexpressed in non-small-cell lung cancer and promotes tumor metastasis by enhancing cell survival and migration. Cancer Res. 71:1156–1166. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF III and Hynes NE: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA. 100:8933–8938. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Smirnova T, Zhou ZN, Flinn RJ, et al: Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene. 31:706–715. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sergina NV, Rausch M, Wang D, et al: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 445:437–441. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Erjala K, Sundvall M, Junttila TT, et al: Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res. 12:4103–4111. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Linn D, Liu Z, et al: EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. Mol Cancer Ther. 7:3176–3186. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Desbois-Mouthon C, Baron A, Blivet-Van Eggelpoël MJ, et al: Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res. 15:5445–5456. 2009. | |
|
Frogne T, Benjaminsen RV, Sonne-Hansen K, et al: Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat. 114:263–275. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Engelman JA, Zejnullahu K, Mitsudomi T, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007. View Article : Google Scholar | |
|
Grøvdal LM, Kim J, Holst MR, Knudsen SLJ, Grandal MV and van Deurs B: EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells. Cell Signal. 24:296–301. 2012.PubMed/NCBI | |
|
McDonagh CF, Huhalov A, Harms BD, et al: Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther. 11:582–593. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sithanandam G, Fornwald LW, Fields JR, Morris NL and Anderson LM: Anti-tumor efficacy of naked siRNAs for ERBB3 or AKT2 against lung adenocarcinoma cell xenografts. Int J Cancer. 130:251–258. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Engelman JA, Jänne PA, Mermel C, et al: ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA. 102:3788–3793. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Ogino A, Kitao H, Hirano S, et al: Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non-small cell lung cancer cell line. Cancer Res. 67:7807–7814. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Sequist LV, Waltman BA, Dias-Santagata D, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 3:75ra262011. View Article : Google Scholar : PubMed/NCBI | |
|
Kwak E: The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer. Oncologist. 16:1498–1507. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Ling B, Wang GX, Long G, Qiu JH and Hu ZL: Tumor suppressor miR-22 suppresses lung cancer cell progression through post-transcriptional regulation of ErbB3. J Cancer Res Clin Oncol. 138:1355–1361. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kawano O, Sasaki H, Endo K, et al: ErbB3 mRNA expression correlated with specific clinicopathologic features of Japanese lung cancers. J Surg Res. 146:43–48. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Vaught DB, Stanford JC, Young C, et al: HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res. 72:2672–2682. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lee-Hoeflich ST, Crocker L, Yao E, et al: A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 68:5878–5887. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Agus DB, Akita RW, Fox WD, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2:127–137. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Göstring L, Malm M, Höidén-Guthenberg I, et al: Cellular effects of HER3-specific affibody molecules. PLoS One. 7:e400232012.PubMed/NCBI | |
|
Weiner DB, Kokai Y, Wada T, Cohen JA, Williams WV and Greene MI: Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein. Oncogene. 4:1175–1183. 1989.PubMed/NCBI | |
|
Menendez JA and Lupu R: Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited? Breast Cancer Res. 9:1112007. View Article : Google Scholar : PubMed/NCBI | |
|
Iorio MV and Croce CM: MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yao E, Zhou W, Lee-Hoeflich ST, et al: Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res. 15:4147–4156. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Junttila TT, Akita RW, Parsons K, et al: Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 15:429–440. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Chakrabarty A, Sánchez V, Kuba MG, Rinehart C and Arteaga CL: Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci USA. 109:2718–2723. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kim JH, Im KS, Kim NH, Yhee JY, Nho WG and Sur JH: Expression of HER-2 and nuclear localization of HER-3 protein in canine mammary tumors: histopathological and immunohistochemical study. Vet J. 189:318–322. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chiu CG, Masoudi H, Leung S, et al: HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients. Ann Surg. 251:1107–1116. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Giltnane JM, Moeder CB, Camp RL and Rimm DL: Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Cancer. 115:2400–2409. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Haas S, Gevensleben H, Rabstein S, et al: Expression of heregulin, phosphorylated HER-2, HER-3 and HER-4 in HER-2 negative breast cancers. Oncol Rep. 21:299–304. 2009.PubMed/NCBI | |
|
Gori S, Foglietta J, Mameli MG, et al: HER-3 status by immunohistochemistry in HER-2-positive metastatic breast cancer patients treated with trastuzumab: correlation with clinical outcome. Tumori. 98:39–44. 2012.PubMed/NCBI | |
|
Yoshioka T, Nishikawa Y, Ito R, et al: Significance of integrin αvβ5 and erbB3 in enhanced cell migration and liver metastasis of colon carcinomas stimulated by hepatocyte-derived heregulin. Cancer Sci. 101:2011–2018. 2010. | |
|
Scartozzi M, Mandolesi A, Giampieri R, et al: The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. Oncologist. 16:53–60. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang XL, Yang YS, Xu DP, et al: Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg. 33:2112–2118. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu S, Belkhiri A and El-Rifai W: DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib. Gastroenterology. 141:1738–1748. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Moelans CB, van Diest PJ, Milne AN and Offerhaus GJ: Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int. 2011:6741822010.PubMed/NCBI | |
|
te Velde EA, Franke AC, van Hillegersberg R, et al: HER-family gene amplification and expression in resected pancreatic cancer. Eur J Surg Oncol. 35:1098–1104. 2009.PubMed/NCBI | |
|
Hirakawa T, Nakata B, Amano R, et al: HER3 overexpression as an independent indicator of poor prognosis for patients with curatively resected pancreatic cancer. Oncology. 81:192–198. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Buck E, Eyzaguirre A, Haley JD, Gibson NW, Cagnoni P and Iwata KK: Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol Cancer Ther. 5:2051–2059. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Hsieh SY, He JR, Yu MC, et al: Secreted ERBB3 isoforms are serum markers for early hepatoma in patients with chronic hepatitis and cirrhosis. J Proteome Res. 10:4715–4724. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Blivet-Van Eggelpoël MJ, Chettouh H, Fartoux L, et al: Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol. 57:108–115. 2012.PubMed/NCBI | |
|
Sheng Q, Liu X, Fleming E, et al: An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell. 17:298–310. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tanner B, Hasenclever D, Stern K, et al: ErbB-3 predicts survival in ovarian cancer. J Clin Oncol. 24:4317–4323. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Leng J, Lang J, Shen K and Guo L: Overexpression of p53, EGFR, c-erbB2 and c-erbB3 in endometrioid carcinoma of the ovary. Chin Med Sci J. 12:67–70. 1997.PubMed/NCBI | |
|
Soler M, Mancini F, Meca-Cortes O, et al: HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells. Int J Cancer. 125:2565–2575. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Buac K, Xu M, Cronin J, Weeraratna AT, Hewitt SM and Pavan WJ: NRG1/ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation. Pigment Cell Melanoma Res. 22:773–784. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ueno Y, Sakurai H, Tsunoda S, et al: Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells. Int J Cancer. 123:340–347. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Belleudi F, Marra E, Mazzetta F, et al: Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells. Cell Cycle. 11:1455–1467. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Djerf Severinsson EA, Trinks C, Gréen H, et al: The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays antitumor activity in vivo. Biochem Biophys Res Commun. 414:563–568. 2011.PubMed/NCBI |
